Design Therapeutics vs Opus Genetics
DSGN and IRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DSGN and IRD compare
Design Therapeutics is the larger company, worth 1.9 times as much as Opus Genetics ($674M against $359M).
Design Therapeutics scores higher on the StockData Score (7 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DSGN | IRD |
|---|---|---|
| Size and price | ||
| Market cap | $674M | $359M |
| Share price | $10.77 | $4.31 |
| Change, 1 year | 45.0% | 119% |
| Change, 5 years | −47.5% | 18.4% |
| Beta (5Y) | 1.69 | 0.98 |
| Employees | 54 | 27 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 45.3× |
| P/B | 3.3× (better) | 9.3× |
| FCF yield | −8.8% | – |
| Fair value | – | $0.739 |
| Margin of safety | – | −483% |
| Growth | ||
| Revenue growth (TTM) | – | −45.9% |
| Profitability | ||
| Operating margin | – | −778% |
| Net margin | – | −1727% |
| Return on equity | −36.9% (better) | −616% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −217.5× |
| Current ratio | 16.78 (better) | 9.65 |
| Altman Z-score | 25.24 (better) | −1.73 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −9.2% | −0.68% (better) |
| Shareholder yield | −9.2% | −0.68% (better) |
| Ownership | ||
| Held by institutions | 69.2% | 72.8% |
| Held by insiders | 21.2% | 37.6% |
| Insider net buying, 12 months | – | −$19.4M |
| Short interest, % of float | 12.8% | 20.9% |
Go deeper
- DSGN stock overview
- DSGN income statement
- DSGN valuation and score
- IRD stock overview
- IRD income statement
- IRD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.